Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Core Insights - Galapagos NV has appointed Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors, effective July 28, 2025, replacing Peter Guenter and Simon Sturge [1][2] - The appointments are aimed at strengthening the Board and enhancing long-term value creation, with both new directors bringing extensive experience in the biopharmaceutical sector [2] Company Overview - Galapagos is a biotechnology company focused on transforming patient outcomes through innovative science and technology, with operations in Europe, the U.S., and Asia [4] - The company aims to address high unmet medical needs and is committed to developing a pipeline of best-in-class medicines [4] New Directors' Background - Dawn Svoronos has over 30 years of experience in the biopharmaceutical industry, including significant roles at Merck, where she led operations across 30 European markets and was involved in post-merger integration [2][3] - Jane Griffiths has extensive international corporate leadership experience, having served as Global Head of Actelion Ltd and held senior roles at Johnson & Johnson, focusing on corporate governance and sustainability initiatives [3]